VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+11.92%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| 1 |
D.R. Horton
DHI
|
$987K |
| 2 |
Lennar Class A
LEN
|
$952K |
| 3 |
Freeport-McMoran
FCX
|
$917K |
| 4 |
TJX Companies
TJX
|
$909K |
| 5 |
Ametek
AME
|
$905K |
Top Sells
| 1 |
Steel Dynamics
STLD
|
$1.65M |
| 2 |
NOA
North American Construction
NOA
|
$1.55M |
| 3 |
Alamos Gold
AGI
|
$1.53M |
| 4 |
Cheniere Energy
CQP
|
$1.51M |
| 5 |
GTY
Getty Realty Corp
GTY
|
$1.5M |
Sector Composition
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Gilead Sciences
GILD
$143B
| $294K | 0.15% |
3,423
-651
| -16% | -$55.9K |
|
277
Amgen
AMGN
$153B
| $293K | 0.15% |
1,116
+115
| +11% | +$30.2K |
|
278
Immunocore
IMCR
$1.87B
| $293K | 0.15% |
5,131
-3,507
| -41% | -$200K |
|
279
Axsome Therapeutics
AXSM
$6.25B
| $293K | 0.15% |
3,795
-6,618
| -64% | -$510K |
|
280
PTC Therapeutics
PTCT
$4.55B
| $292K | 0.15% |
7,648
-1,529
| -17% | -$58.4K |
|
281
Invesco Senior Income Trust
VVR
$555M
| $292K | 0.15% |
76,161
-21,299
| -22% | -$81.6K |
|
282
Legend Biotech
LEGN
$6.66B
| $291K | 0.15% |
5,832
+481
| +9% | +$24K |
|
|
IMGN
283
DELISTED
Immunogen Inc
IMGN
| $290K | 0.15% |
58,521
+26,180
| +81% | +$130K |
|
|
EVF
284
Eaton Vance Senior Income Trust
EVF
$101M
| $290K | 0.15% |
55,036
-6,929
| -11% | -$36.5K |
|
285
Biogen
BIIB
$20.6B
| $290K | 0.15% |
1,047
-168
| -14% | -$46.5K |
|
|
NOA
286
North American Construction
NOA
$390M
| $290K | 0.15% |
21,685
-115,927
| -84% | -$1.55M |
|
287
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $290K | 0.15% |
19,345
-9,062
| -32% | -$136K |
|
288
BioMarin Pharmaceuticals
BMRN
$11.1B
| $289K | 0.15% |
2,792
-502
| -15% | -$52K |
|
|
BTX
289
BlackRock Technology and Private Equity Term Trust
BTX
$819M
| $286K | 0.15% |
41,928
+9,450
| +29% | +$64.4K |
|
290
BlackRock Floating Rate Income Trust
BGT
$317M
| $285K | 0.15% |
26,015
-5,124
| -16% | -$56.1K |
|
291
Harmony Biosciences
HRMY
$2.07B
| $284K | 0.15% |
5,159
-137
| -3% | -$7.55K |
|
|
BPMC
292
DELISTED
Blueprint Medicines
BPMC
| $284K | 0.15% |
6,474
+1,309
| +25% | +$57.3K |
|
|
EFT
293
Eaton Vance Floating-Rate Income Trust
EFT
$319M
| $282K | 0.15% |
25,471
-3,092
| -11% | -$34.3K |
|
294
BlackRock Floating Rate Income Strategies Fund
FRA
$471M
| $281K | 0.15% |
24,938
-4,304
| -15% | -$48.5K |
|
295
Aurinia Pharmaceuticals
AUPH
$1.63B
| $280K | 0.15% |
64,786
+39,866
| +160% | +$172K |
|
|
SAGE
296
DELISTED
Sage Therapeutics
SAGE
| $279K | 0.15% |
7,320
-68
| -0.9% | -$2.59K |
|
297
Gladstone Capital
GLAD
$582M
| $279K | 0.15% |
14,500
-4,812
| -25% | -$92.6K |
|
298
Agios Pharmaceuticals
AGIO
$2.09B
| $274K | 0.14% |
9,753
-4,050
| -29% | -$114K |
|
299
Oaktree Specialty Lending
OCSL
$1.23B
| $268K | 0.14% |
13,013
-3,935
| -23% | -$81.1K |
|
300
Zai Lab
ZLAB
$3.42B
| $265K | 0.14% |
8,625
-1,187
| -12% | -$36.4K |
|